[{"address1": "700 Saginaw Drive", "city": "Redwood City", "state": "CA", "zip": "94063", "country": "United States", "phone": "650 481 6801", "website": "https://www.revmed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.", "fullTimeEmployees": 616, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mark A. Goldsmith Ph.D.", "age": 62, "title": "CEO, President & Chairman", "yearBorn": 1962, "fiscalYear": 2024, "totalPay": 1347967, "exercisedValue": 10163472, "unexercisedValue": 51843852}, {"maxAge": 1, "name": "Mr. Jack  Anders", "age": 47, "title": "Chief Financial Officer", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 725633, "exercisedValue": 849639, "unexercisedValue": 2896538}, {"maxAge": 1, "name": "Ms. Margaret A. Horn J.D.", "age": 61, "title": "Chief Operating Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 897933, "exercisedValue": 3021392, "unexercisedValue": 16625696}, {"maxAge": 1, "name": "Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.", "age": 63, "title": "President of Research & Development", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 951933, "exercisedValue": 4257259, "unexercisedValue": 11511893}, {"maxAge": 1, "name": "Ms. Xiaolin  Wang", "age": 54, "title": "Executive Vice President of Development", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 701200, "exercisedValue": 0, "unexercisedValue": 13540803}, {"maxAge": 1, "name": "Dr. Martin D. Burke M.D., Ph.D.", "title": "Co-Founder & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael A. Fischbach Ph.D.", "age": 43, "title": "Academic Co-Founder & Member of Scientific Advisory Board", "yearBorn": 1981, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kevan M. Shokat Ph.D.", "title": "Academic Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Walter  Reiher Ph.D.", "title": "Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jan  Smith Ph.D.", "title": "Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 40.2, "open": 40.49, "dayLow": 40.15, "dayHigh": 41.94, "regularMarketPreviousClose": 40.2, "regularMarketOpen": 40.49, "regularMarketDayLow": 40.15, "regularMarketDayHigh": 41.94, "payoutRatio": 0.0, "beta": 1.096, "forwardPE": -10.1456785, "volume": 1234377, "regularMarketVolume": 1234377, "averageVolume": 1856930, "averageVolume10days": 2061670, "averageDailyVolume10Day": 2061670, "bid": 29.63, "ask": 52.41, "bidSize": 2, "askSize": 2, "marketCap": 7653752320, "fiftyTwoWeekLow": 29.17, "fiftyTwoWeekHigh": 62.4, "fiftyDayAverage": 37.9883, "twoHundredDayAverage": 43.567776, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 5685400576, "profitMargins": 0.0, "floatShares": 168227532, "sharesOutstanding": 186268000, "sharesShort": 18880783, "sharesShortPriorMonth": 16427758, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.1014, "heldPercentInsiders": 0.01994, "heldPercentInstitutions": 1.05953, "shortRatio": 9.58, "shortPercentOfFloat": 0.1079, "impliedSharesOutstanding": 186268000, "bookValue": 11.157, "priceToBook": 3.6828897, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -697505984, "trailingEps": -4.01, "forwardEps": -4.05, "enterpriseToEbitda": -7.263, "52WeekChange": 0.03085804, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 41.09, "targetHighPrice": 88.0, "targetLowPrice": 57.0, "targetMeanPrice": 72.36364, "targetMedianPrice": 72.0, "recommendationMean": 1.33333, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 11, "totalCash": 2102674944, "totalCashPerShare": 11.288, "ebitda": -782745024, "totalDebt": 134342000, "quickRatio": 13.258, "currentRatio": 13.459, "debtToEquity": 6.464, "returnOnAssets": -0.2309, "returnOnEquity": -0.36676, "grossProfits": -679953024, "freeCashflow": -349126624, "operatingCashflow": -591310976, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "RVMD", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Revolution Medicines, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1581604200000, "postMarketChangePercent": 0.0, "postMarketPrice": 41.09, "postMarketChange": 0.0, "regularMarketChange": 0.889999, "regularMarketDayRange": "40.15 - 41.94", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1856930, "fiftyTwoWeekLowChange": 11.92, "fiftyTwoWeekLowChangePercent": 0.408639, "fiftyTwoWeekRange": "29.17 - 62.4", "fiftyTwoWeekHighChange": -21.310001, "fiftyTwoWeekHighChangePercent": -0.34150642, "fiftyTwoWeekChangePercent": 3.085804, "earningsTimestamp": 1746648120, "earningsTimestampStart": 1754391540, "earningsTimestampEnd": 1754913600, "earningsCallTimestampStart": 1746649800, "earningsCallTimestampEnd": 1746649800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -4.01, "epsForward": -4.05, "epsCurrentYear": -4.6525, "priceEpsCurrentYear": -8.831811, "fiftyDayAverageChange": 3.1016998, "fiftyDayAverageChangePercent": 0.08164882, "twoHundredDayAverageChange": -2.4777756, "twoHundredDayAverageChangePercent": -0.05687175, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.3 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": 2.21393, "regularMarketPrice": 41.09, "corporateActions": [], "postMarketTime": 1749247187, "regularMarketTime": 1749240000, "exchange": "NMS", "messageBoardId": "finmb_283775412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "shortName": "Revolution Medicines, Inc.", "marketState": "CLOSED", "displayName": "Revolution Medicines", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]